Results 121 to 130 of about 18,512,812 (309)

A Dirichlet-multinomial mixed model for determining differential abundance of mutational signatures

BMC Bioinformatics
Background Mutational processes of diverse origin leave their imprints in the genome during tumour evolution. These imprints are called mutational signatures and they have been characterised for point mutations, structural variants and copy number ...
Lena Morrill Gavarró, Dominique-Laurent Couturier, Florian Markowetz   +2 more
doaj   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis

Nature Communications, 2017
Tumorigenesis is a complex process driven by numerous risk factors. Here, genomic analysis of liver cancer reveals the evolution of mutational signatures during tumor development, highlighting mutational and structural signatures linked to environmental ...
Eric Letouzé, Jayendra Shinde, Victor Renault, Gabrielle Couchy, Jean-Frédéric Blanc, Emmanuel Tubacher, Quentin Bayard, Delphine Bacq, Vincent Meyer, Jérémy Semhoun, Paulette Bioulac-Sage, Sophie Prévôt, Daniel Azoulay, Valérie Paradis, Sandrine Imbeaud, Jean-François Deleuze, Jessica Zucman-Rossi   +16 more
doaj   +1 more source

On‐treatment dynamics of circulating extracellular vesicles in the first‐line setting of patients with advanced non‐small cell lung cancer: the LEXOVE prospective study

Molecular Oncology, EarlyView.
The LEXOVE prospective study evaluated plasma cell‐free extracellular vesicle (cfEV) dynamics using Bradford assay and dynamic light scattering in metastatic non‐small cell lung cancer patients undergoing first‐line treatments, correlating a ∆cfEV < 20% with improved median progression‐free survival in responders versus non‐responders.
Valerio Gristina, Viviana Bazan, Nadia Barraco, Simona Taverna, Mauro Manno, Samuele Raccosta, Anna Paola Carreca, Marco Bono, Tancredi Didier Bazan Russo, Francesco Pepe, Pasquale Pisapia, Lorena Incorvaia, Giuseppe Badalamenti, Giancarlo Troncone, Umberto Malapelle, Daniele Santini, Antonio Russo, Antonio Galvano   +17 more
wiley   +1 more source

Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients

Molecular Oncology, EarlyView.
We quantified and cultured circulating tumor cells (CTCs) of 62 patients with various cancer types and generated CTC‐derived tumoroid models from two salivary gland cancer patients. Cellular liquid biopsy‐derived information enabled molecular genetic assessment of systemic disease heterogeneity and functional testing for therapy selection in both ...
Nataša Stojanović Gužvić, Florian Lüke, Steffi Treitschke, Andrea Coluccio, Martin Hoffmann, Giancarlo Feliciello, Adithi Ravikumar Varadarajan, Xin Lu, Kathrin Weidele, Catherine Botteron, Silvia Materna–Reichelt, Felix Keil, Katja Evert, Florian Weber, Thomas Schamberger, Michael Althammer, Jirka Grosse, Dirk Hellwig, Christian Schulz, Stephan Seitz, Peter Ugocsai, Anke Schlenska‐Lange, Roman Mayr, Ulrich Kaiser, Wolfgang Dietmaier, Bernhard Polzer, Jens Warfsmann, Kamran Honarnejad, Tobias Pukrop, Daniel Heudobler, Christoph A. Klein, Christian Werno   +31 more
wiley   +1 more source

Biallelic Mutation-Drift Diffusion in the Limit of Small Scaled Mutation Rates [PDF]

arXiv, 2014
The evolution of the allelic proportion $x$ of a biallelic locus subject to the forces of mutation and drift is investigated in a diffusion model, assuming small scaled mutation rates. The overall scaled mutation rate is parametrized with $\theta=(\mu_1+\mu_0)N$ and the ratio of mutation rates with $\alpha=\mu_1/(\mu_1+\mu_0)=1-\beta$.
arxiv  

Biological evolution through mutation, selection, and drift: An introductory review [PDF]

, 1999
Motivated by present activities in (statistical) physics directed towards biological evolution, we review the interplay of three evolutionary forces: mutation, selection, and genetic drift. The review addresses itself to physicists and intends to bridge the gap between the biological and the physical literature.
arxiv   +1 more source

Circulating tumor DNA (ctDNA) trajectories predict survival in trifluridine/tipiracil‐treated metastatic colorectal cancer patients

Molecular Oncology, EarlyView.
The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld, Stefan Kühberger, Ricarda Graf, Christine Beichler, Markus Braun, Nadia Dandachi, Ellen Heitzer, Gerald W. Prager   +7 more
wiley   +1 more source

Great ape mutation spectra vary across the phylogeny and the genome due to distinct mutational processes that evolve at different rates

bioRxiv, 2019
Recent studies of hominoid variation have shown that mutation rates and spectra can evolve rapidly, contradicting the fixed molecular clock model.
M. Goldberg, Kelley Harris
semanticscholar   +1 more source

NanoCMSer: a consensus molecular subtype stratification tool for fresh‐frozen and paraffin‐embedded colorectal cancer samples

Molecular Oncology, EarlyView.
Consensus molecular subtypes (CMS1‐4) have been identified to study colorectal cancer heterogeneity and serve as potential biomarkers. In this study, we developed and evaluated NanoCMSer, a NanoString‐based classifier using 55 genes, optimized for FF and FFPE to facilitate the clinical evaluation of CMS subtyping.
Arezo Torang, Simone van de Weerd, Veerle Lammers, Sander van Hooff, Inge van den Berg, Saskia van den Bergh, Miriam Koopman, Jan N. IJzermans, Jeanine M. L. Roodhart, Jan Koster, Jan Paul Medema   +10 more
wiley   +1 more source